

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**23 April 2022 :: Issue 654**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

*Comments and suggestions should be directed to*  
*David R. Curry, MS*  
*Editor and*  
*Executive Director*  
*Center for Vaccine Ethics & Policy*  
*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

**Request email delivery of the pdf:** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

**Support this knowledge-sharing service:** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents [click to move among sections]**

- :: [Coronavirus \[COVID-19\] - WHO](#)*
- :: [Organization Announcements](#)*
- :: [Journal Watch](#)*



## **World Immunization Week 2022 :: 24 – 30 April 2022**


*World Immunization Week 2022 - Long Life for All*

World Immunization Week, celebrated in the last week of April, aims to highlight the collective action needed and to promote the use of vaccines to protect people of all ages against disease.

WHO works with countries across the globe to raise awareness of the value of vaccines and immunization and ensures that governments obtain the necessary guidance and technical support to implement high-quality immunization programmes. The ultimate goal of World Immunization Week is for more people – and their communities – to be protected from vaccine-preventable diseases.

This World Immunization Week 2022 campaign page will be updated regularly during World Immunization Week.

All resources can be downloaded in six languages and open design files [here](#).



## **Over 1 million African children protected by first malaria vaccine**

*Ahead of World Malaria Day (25 April), WHO calls for continued innovation to save lives*  
News release 21 April 2022

As World Malaria Day approaches, more than 1 million children in **Ghana, Kenya and Malawi** have received one or more doses of the world's first malaria vaccine, thanks to a pilot programme coordinated by WHO. **The malaria vaccine pilots, first launched by the Government of Malawi in April 2019, have shown that the RTS,S/AS01 (RTS,S) vaccine is safe and feasible to deliver, and that it substantially reduces deadly severe malaria.**

These findings paved the way for the historic October 2021 WHO recommendation for the expanded use of RTS,S among children living in settings with moderate to high malaria transmission. **If widely deployed, WHO estimates that the vaccine could save the lives of an additional 40 000 to 80 000 African children each year.**

More than US\$ 155 million has been secured from Gavi, the Vaccine Alliance to support the introduction, procurement and delivery of the malaria vaccine for Gavi-eligible countries in sub-Saharan Africa. WHO guidance is available to countries as they consider whether and how to adopt RTS,S as an additional tool to reduce child illness and deaths from malaria.

"As a malaria researcher in my early career, I dreamed of the day we would have an effective vaccine against this devastating disease," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "This vaccine is not just a scientific breakthrough, it's life-changing for families across Africa. It demonstrates the power of science and innovation for health. Even so, there is an urgent need to develop more and better tools to save lives and drive progress towards a malaria-free world."

#### *Prospects for new interventions*

**RTS,S is a first-generation vaccine that could be complemented in the future by other vaccines with similar or higher efficacy. WHO welcomes progress in the development of R21/Matrix-M and other malaria vaccine candidates in early clinical development.** The successful completion of clinical trials for these vaccines will be important to assess their safety and efficacy profiles. WHO also welcomes the news from BioNTech, manufacturer of the Pfizer-BioNTech COVID-19 vaccine, that it aims to develop a malaria vaccine using mRNA technology.

In the field of vector control, a number of new tools and technologies have been submitted to WHO for evaluation. Should they demonstrate efficacy in controlling the disease, WHO will formulate new recommendations or amend existing ones to support their deployment. These include, for example, **new types of insecticide-treated nets, spatial mosquito repellents, gene-drive approaches and sugar baits designed to attract and kill Anopheles mosquitoes.**

There are also new medicines in the pipeline. WHO welcomes the recent approval by the Australian Therapeutic Goods Administration of **dispersible tablets of single-dose tafenoquine for the prevention of P. vivax malaria among children.** Tafenoquine has also been approved for use in adults by the US Federal Drug Administration and by drug regulatory bodies in other countries, including Brazil, Peru and Thailand. As a single dose, tafenoquine is expected to support patient adherence to treatment. The current standard of care requires a 7- or 14-day course of medication.

A number other antimalarial medicines with new modes of action are being developed for the treatment of uncomplicated and severe malaria. Ganaplacide-Lumefantrine, currently in a Phase II clinical trial, is the first non-artemisinin combination therapy and could be an asset in fight against emerging drug-resistant malaria in Africa.

In addition to drug resistance, WHO has reported other pressing threats in the fight against malaria, such as mosquito resistance to insecticides, an invasive malaria vector that thrives in urban and rural areas, and the emergence and spread of mutated P. falciparum parasites that are undermining the effectiveness of rapid diagnostic tests. Innovation in tools and strategies will be critical to contain these threats, together with a more strategic use of the tools that are available today...

.....

:: See *The Lancet* editorial in in Journal Watch below ::

.....

.....

### **[Child immunization programme reaches Rohingya refugee children on Bhasan Char island](#)**

DHAKA, 21 April 2022 – This week, Rohingya refugee children on Bhasan Char in Bangladesh are receiving vaccinations through a routine childhood immunization programme.

UNICEF provides technical and financial assistance to the Government of Bangladesh in support of childhood immunizations on Bhasan Char. While Rohingya refugee children have received some vaccinations since arriving on the island through two ad hoc campaigns, this week marks the inauguration of the first regular childhood immunization programme on Bhasan Char...

“The routine childhood vaccination programme on Bhasan Char follows the Bangladesh Government’s national Expanded Programme on Immunization (EPI). This includes vaccinations against diphtheria, pertussis, tetanus, hepatitis-B, Hib, polio, pneumonia, tuberculosis, measles and rubella,” said Dr Md. Shamsul Haque, Line Director for Maternal Neonatal Child and Adolescent Health, Ministry of Health and Family Welfare.

Rohingya refugee families began to be relocated from the refugee camps in Cox’s Bazar to the island of Bhasan Char just over a year ago. Estimations are that there are now well over 10,000 children on the island. UNICEF, UNHCR, WHO and other partners are working together to support the Government to deliver health and other services on Bhasan Char...

.....

.....

### **[CDC Launches New Center for Forecasting and Outbreak Analytics](#)**

Tuesday, April 19, 2022

Today, the Centers for Disease Control and Prevention (CDC) announced the launch of the [Center for Forecasting and Outbreak Analytics \(CFA\)](#). CFA seeks to enhance the nation’s ability to use data, models, and analytics to enable timely, effective decision-making in response to public health threats for CDC and its public health partners.

**CFA’s goals are to improve outbreak response using infectious disease modeling and analytics and to provide support to leaders at the federal, state, and local levels. CFA will also develop a program to provide insights about infectious disease events to the public to inform individual decision making** – the equivalent of the National Weather Service for infectious diseases.

"I am excited we have launched CDC's Center for Forecasting and Outbreak Analytics," said CDC Director, Rochelle P. Walensky, MD, MPH. "This new center is an example of how we are modernizing the ways we prepare for and respond to public health threats. I am proud of the work that has come out of this group thus far and eager to see continued innovation in the use of data, modeling, and analytics to improve outbreak responses."

**CFA's work will be focused into three main pillars: to predict, inform, and innovate.** CFA has begun to build a world-class outbreak analytics team with experts across several disciplines to develop faster, richer evidence to predict trends and guide decision-making during emergencies. To better inform our partners, CFA is hiring expert communicators to regularly share insights with federal, state, and local partners and the public. CFA will also continue to advance the state of the science of outbreak data, models and analytics to improve the nation's ability to respond to health emergencies.

"The capabilities and team we are building at the new Center will improve decision-making in a health crisis," said Dylan George, PhD, Director for Operations, CFA. "I am proud of the CFA team and excited for the future. Better data and analytics will give us better responses to protect all Americans."

Planning for CFA began in August 2021, with the initial funding of \$200 million from the American Rescue Plan Act. So far, CDC has awarded \$26 million in funding to academic institutions and federal partners to advance modeling and forecasting methodology, with an emphasis on workforce development and health equity. In December 2021, CFA worked with academic partners to assemble models anticipating the Omicron wave and generated early estimates of Omicron severity, giving leaders an opportunity to bolster the response.

.....  
.....

### [Delivering on the G20 Leaders commitment to build an equitable and effective Financial Intermediary Fund \(FIF\) for Pandemic Preparedness and Response \(PPR\)](#)

*Statement* 19 April 2022

*Recommendations to G20 leaders, finance and health ministers from the WHO Council on the Economics of Health for All and the G20 Health and Development Partnership.*

.....  
.....

### **COVAX Guidance, Analysis, Reports**

### [WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator](#)

*22 April 2022*

*Statement*

**Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date.** However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt

and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries.

Pfizer's oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients.

This recommendation is based on new data from two randomized controlled trials involving 3078 patients. The data show that the risk of hospitalization is reduced by 85% following this treatment. In a high-risk group (over 10% risk of hospitalization), that means 84 fewer hospitalizations per 1000 patients.

**WHO suggests against its use in patients at lower risk, as the benefits were found to be negligible.**

**One obstacle for low- and middle-income countries is that the medicine can only be administered while the disease is at its early stages; prompt and accurate testing is therefore essential for a successful outcome with this therapy.** Data collected by [FIND](#) show that the average daily testing rate in low-income countries is as low as one-eightieth the rate in high-income countries. Improving access to early testing and diagnosis in primary health care settings will be key for the global rollout of this treatment.

**WHO is extremely concerned that -- as occurred with COVID-19 vaccines -- low- and middle-income countries will again be pushed to the end of the queue when it comes to accessing this treatment.**

Lack of transparency on the part of the originator company is making it difficult for public health organizations to obtain an accurate picture of the availability of the medicine, which countries are involved in bilateral deals and what they are paying. In addition, a [licensing agreement](#) made by Pfizer with the Medicines Patent Pool limits the number of countries that can benefit from generic production of the medicine.

The originator product, sold under the name Paxlovid, will be included in the WHO prequalification list today, but generic products are not yet available from quality-assured sources. Several generic companies (many of which are covered by the licensing agreement between the Medicines Pool and Pfizer) are in discussion with WHO Prequalification but may take some time to comply with international standards so that they can supply the medicine internationally.

**WHO therefore strongly recommends** that Pfizer make its pricing and deals more transparent and that it enlarge the geographical scope of its licence with the Medicines Patent Pool so that more generic manufacturers may start to produce the medicine and make it available faster at affordable prices.

Along with the strong recommendation for the use of nirmatrelvir and ritonavir, WHO has also updated its recommendation on remdesivir, another antiviral medicine.

Previously, WHO had suggested against its use in all COVID-19 patients regardless of disease severity, due to the totality of the evidence at that time showing little or no effect on mortality. **Following**

**publication of new data from a clinical trial looking at the outcome of admission to hospital, WHO has updated its recommendation. WHO now suggests the use of remdesivir in mild or moderate COVID-19 patients who are at high risk of hospitalization.**

The recommendation for use of remdesivir in patients with severe or critical COVID-19 is currently under review.



**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

***Weekly Epidemiological and Operational updates***

*Last update: 14 Apr 2022*

**Confirmed cases ::** 505 817 953


**Confirmed deaths ::** 6 213 876

**Vaccine doses administered:** 11 324 805 837



**Weekly epidemiological update on COVID-19 - 20 April 2022**

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 17 April 2022\*\***



*Overview*

Globally, the number of new COVID-19 cases and deaths has continued to decline since the end of March 2022. During the week of 11 through 17 April 2022, over 5 million cases and over 18 000 deaths were reported across the six WHO regions, a 24% and 12% decrease respectively, as compared to the previous week.

As of 17 April 2022, over 500 million confirmed cases and over 6 million deaths have been reported globally.

In this edition, we provide updates on circulating SARS-CoV-2 variants of concern (VOCs) and a special focus on applying Geographic Information Systems to the COVID-19 response

.....  
.....

### **[Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022](#)**

*[Full scale view available at title link above]*

*[Updated on 23 Apr 2022]*

.....

### **COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements**

*[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]*

#### **AstraZeneca**

##### **[Press Releases](#)**

##### **[Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations](#)**

20 April 2022

*:: Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in Evusheld group*

*:: Data published in the New England Journal of Medicine*

#### **Bharat Biotech**

*[Press Releases](#) - No new company announcements identified*

#### **BioCubaFarma – Cuba**

*[Últimas Noticias](#) - Website not leading at inquiry*

#### **Biological E**

*[News](#) - No new digest announcements identified*

#### **Biontech**

*[Press Releases](#) - No new digest announcements identified*

#### **CanSinoBIO**

*[News](#) - Website not responding at inquiry*

#### **CIGB**

*[Latest News](#) - No new digest announcements identified*



## **Cinagen**

Recent News - No new digest announcements identified

## **Clover Biopharmaceuticals** - China

News

Apr 20, 2022

[\*\*Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease\*\*](#)

Apr 19, 2022

[\*\*Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022\*\*](#)

## **Curevac [Bayer Ag – Germany]**

News

April 21, 2022

[\*\*CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study\*\*](#)

:: Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study

:: Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals

:: Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants

## **Gamaleya National Center**

Latest News and Events - See Russia below.

## **IMBCAMS**, China

Home - Website not responding at inquiry

## **Janssen/JNJ**

Press Releases - No new digest announcements identified

## **Medicago**

Media - No new digest announcements identified

## **Moderna**

Press Releases

19 April, 2022

[\*\*Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform\*\*](#)

:: Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was maintained for six months after booster for the Beta and Omicron variants

:: Tolerability and safety of the bivalent booster were consistent with authorized 50 µg mRNA-1273 booster

:: Moderna is evaluating an updated bivalent booster incorporating more Omicron-specific mutations (mRNA-1273.214) in a Phase 2/3 clinical study; initial data on this candidate, expected in the second quarter, will inform selection of fall 2022 booster for Northern Hemisphere

## **Nanogen**

*News - No new digest announcements identified*

## **Novavax**

*Press Releases*

Apr 22, 2022

[\*\*Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial\*\*](#)

Apr 20, 2022

[\*\*Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine\*\*](#)

Apr 19, 2022

[\*\*Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan\*\*](#)

Apr 18, 2022

[\*\*Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases\*\*](#)

## **Pfizer**

*Recent Press Releases*

04.14.2022

[\*\*Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age\*\*](#)

## **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

*Press Releases - No new digest announcements identified*

## **Serum Institute of India**

*NEWS & ANNOUNCEMENTS - No new digest announcements identified*

## **Shifa Pharmed [Iran]**

<http://shafapharmed.com/>

*No news page identified.*

## **Sinopharm/WIBPBIBP**

*News - No new digest announcements identified*

## **Sinovac**

*Press Releases*

[\*\*SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\*\*](#)

2022/04/17

**Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

**WestVac Biopharma**

Media - No new digest announcements identified

**Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

**GSK**

Press releases for media - No new digest announcements identified

**Merck**

News releases - No new digest announcements identified

**Novartis**

News - No new digest announcements identified

**SK Biosciences**

Press releases - No new digest announcements identified

**Valneva**

Press Releases - No new digest announcements identified

.....

.....

**[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 23 Apr 2022](#)**

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



35

vaccines approved for use by at least one national regulatory authority <sup>1</sup>



10

vaccines in WHO's Emergency Use Listing



17.7bn

doses secured globally



\$2 - \$40

reported vaccine price range per dose



2.8bn

doses COVAX has secured, optioned, or received as donations



1.43bn

doses shipped through COVAX to 145 countries


.....

.....

## **COVID-19 Global Targets and Progress Tracker - IMF**

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

**Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)**



The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.





.....  
.....

### **Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.


**Dashboard on Vaccine Equity** [accessed 23 Apr 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



## Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>



## Duke – Launch and Scale Speedometer

### [The Race for Global COVID-19 Vaccine Equity](#)

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables

and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)



[See our COVID Vaccine Donations & Exports research](#)

1.1 Shipped donations: filter by category      1.2 Shipped donations: filter by country

### Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.  
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:



Data updated on Apr 21st 2022



### COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

**COVID-19 Vaccine Roll-out**

**23 Apr 2022** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 506M total confirmed cases; 6.2M total confirmed deaths**  
**Global vaccines administered: 11.5B**

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 290M

Other Delivered (Number of Doses): 270M

Total Delivered (Number of Doses): 550M

Total Administered (Number of Doses): 390M

.....  
.....


### **Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **23 Apr 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....  
.....

### ***Our World in Data***


**[Coronavirus \(COVID-19\) Vaccinations](#)** [Accessed 23 Apr 2022]

- [65%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- [11.5 billion doses](#) have been administered globally, and [10.77 million](#) are now administered each day.
- Only [15.2%](#) of people in low-income countries have received at least one dose.

## Share of people who completed the initial COVID-19 vaccination protocol, Apr 21, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 23 April 2022

OurWorldInData.org/coronavirus • CC BY


Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

## Share of people who completed the initial COVID-19 vaccination protocol, Apr 21, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 23 April 2022

OurWorldInData.org/coronavirus • CC BY

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.



.....  
.....

## **U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **HHS**

#### News

*No new digest content identified.*

### **BARDA-ASPR – U.S. Department of HHS** [to 23 Apr 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

#### News

[ASPR funding expands manufacturing capacity for prefilled injectors to administer vaccines, medicines](#)

Thursday, April 21, 2022

.....

### **FDA**

#### Press Announcements

*No new digest content identified.*

#### Regulatory Actions

### **Vaccines and Related Biological Products Advisory Committee- FDA**

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

#### Calendar

*No new calendar dates identified.*

.....

### **White House [U.S.]** [to 23 Apr 2022]

#### Briefing Room – Selected Major COVID Announcements

#### Press Statement - COVID Context

[Joint Statement Between the United States, Belize, Germany, Indonesia, and Senegal on the Announcement of the Second Global COVID-19 Summit](#)

April 18, 2022 *Statements and Releases*

The United States as first COVID Summit Chair, Belize, as CARICOM Chair; Germany, holding the G7 Presidency; Indonesia, holding the G20 Presidency; and Senegal as African Union Chair, are pleased to announce we will co-host the second Global COVID-19 Summit, which will be held virtually on May 12, 2022. The Summit will redouble our collective efforts to end the acute phase of the COVID-19 pandemic and prepare for future health threats...

### **U.S. Department of State** [to 23 Apr 2022]

<https://www.state.gov/coronavirus/releases/>

#### Press Statement - COVID Context

No new digest content identified.

**USAID** [to 23 Apr 2022]

<https://www.usaid.gov/news-information/press-releases>

*Selected Press Releases, Statements, Announcements*

**[The United States Reaffirms Commitment to Ukraine with \\$131 Million for Resilience, Democracy, Economic Growth, and Healthcare](#)**

April 22, 2022

The United States, through the U.S. Agency for International Development (USAID), will invest \$131 million to counter the impact of Russia's brutal war on the Ukrainian people and to strengthen Ukraine's resilience, democracy, economy, and healthcare systems.

**[The United States Provides Nearly \\$313 Million in Additional Humanitarian Assistance to People in Northern Ethiopia](#)**

April 21, 2022

Press Release

The United States, through the U.S. Agency for International Development (USAID) is providing nearly \$313 million in additional humanitarian assistance to help people affected by the ongoing conflict in northern Ethiopia. Across the Afar, Amhara, and Tigray regions, continued fighting and lack of humanitarian access has left as many as 9 million people facing severe food insecurity and has forced more than 2 million people to flee their homes. In Tigray alone, more than 90 percent of people need aid, while across all three northern regions as many as 1 million people are projected to face famine-like conditions by June.

**[United States Contributes \\$500 Million to World Bank Multi-Donor Trust Fund to Help Government of Ukraine Sustain Operations](#)**

April 20, 2022

Press Release

The United States, through the U.S. Agency for International Development (USAID), is contributing \$500 million to the World Bank's Multi-Donor Trust Fund for Ukraine (MDTF), fully implementing President Biden's commitment to President Zelenskyy that the United States intends to provide the Ukrainian government with direct budgetary aid during their March 30 call. The United States remains committed to supporting Ukraine and its people in the wake of Russia's unprovoked and unjustified war.

.....  
.....

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**European Medicines Agency**

*[News & Press Releases](#)*

*Press Releases*

**[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 19-22 April 2022](#)**

News 22/04/2022

.....

## European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*Latest Updates [Selected]*

*Publication*

### [Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA](#)

Technical report - 21 Apr 2022

This report provides an updated overview of the progress with national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on:


- :: overall vaccine uptake and uptake by target group;
- :: vaccination strategies and policies;
- :: challenges and good practice with the roll-out, including vaccine acceptance and uptake.

*News*

### [Update: Hepatitis of unknown origin in children](#)

News story - 19 Apr 2022

.....



*Accessed 23 Apr 2022*

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

## European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

*Latest [Selected]*

*Press release 23 April 2022*

### [Digital Services Act: Commission welcomes political agreement on rules ensuring a safe and accountable online environment](#)

The Commission welcomes the swift political agreement reached today between the European Parliament and EU Member States on the proposal on the Digital Services Act (DSA), proposed by the Commission in December 2020.

Press release 21 April 2022

**Lebanon: €20 million in humanitarian aid for the most vulnerable people**

Soaring food prices caused by Russia's war in Ukraine are adding further strain to the compounding crises in Lebanon, which imports 96% of its wheat from Russia and Ukraine.

Press release 17 April 2022


**Ukraine: EU boosts humanitarian aid with additional €50 million**

As heavy fighting and missile strikes continue to destroy critical civilian infrastructure, humanitarian needs in Ukraine remain extremely high.

.....  
.....

**Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**

<https://africacdc.org/covid-19-vaccination/>



.....

.....

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[No new digest content identified]

.....

.....

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
23 April 2022, 08:00 IST  
(GMT+5:30)

(↑↓ Status change since  
yesterday)

Active (0.04%)

15079 (838↑)

Discharged (98.75%)

42517724 (1656↑)

Deaths (1.21%)

522149 (33↑)

COVID-19 Vaccination  
as on : 23 April 2022,  
08:00 IST (GMT+5:30)

Total Vaccination : 1,87,46,72,536 (19,13,296↑)

### Government of India – Press Information Bureau

Latest Press Releases

#### COVID - 19 Vaccination Update - Day 463

:: India's cumulative vaccination coverage crosses 187.65 Crore

:: More than 17lakh Vaccine doses administered today till 7 pm

Posted On: 23 APR 2022 8:09PM by PIB Delhi

### Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....

.....

## China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

### Anger mounts among locked-down Shanghai residents as city reports more COVID deaths

By David Stanway

Reuters April 23, 2022 4:38 AM EDT

.....  
.....

## **GPEI Polio**

### **Polio this week as of 20 April 2022**

#### *Headlines*

:: On 26 April, the programme will **launch the new investment case for the GPEI's Strategy: Delivering on a Promise**. This one-hour, virtual event, "Investing in the Promise of a Polio-free World", will feature live remarks from WHO Director-General Dr Tedros Adhanom Ghebreyesus and UNICEF Executive Director Catherine Russell, as well as the stories of health workers and Ministers of Health working with the polio programme around the world. Please [register here](#) to learn more about the financial and political support needed to end polio for good.

:: "Today we have the team from the Polio eradication programme at the stadium, they have been instrumental in vaccinating children by going door to door to eradicate this disease. Sometimes, things are more important than a bat and ball and a pitch, and even a test series, no matter how long people have been waiting to see it. What a great initiative!" [Read more...](#)

#### ***Summary of new polioviruses this week:***

- **DR Congo:** six cVDPV2 cases
- **Nigeria:** one cVDPV2 case
- **Yemen:** 34 cVDPV2 cases

.....

### **UN OCHA – Current Emergencies**

#### *Current Corporate Emergencies*

#### **Afghanistan**

*No new updates identified.*

#### ***Northern Ethiopia***

### **Ethiopia Humanitarian Bulletin | 18 April 2022**

Format - Situation Report

Source - [OCHA](#)

Posted - 18 Apr 2022

#### *Highlights*

- Humanitarian partners have not been able to move any additional aid supplies into Tigray by road since the convoy entered on 1 and 2 April.
- About 36 metric tons of HIV medical supplies were airlifted to Mekelle, the first time since July 2021. It will be enough to provide treatment for 46,000 patients for six months.
- Authorities in Amhara relocated more than 20,000 people out of the planned 70,000 people in North Wello and Wag Hamra zones to new designated sites since mid-March.
- WFP assisted over 35,000 people with food in Gulina, Barahle and Dalole woredas in Afar during the reporting period, reaching over 235,000 people since last week of February.
- More than 11,000 children under five and pregnant and lactating women received supplementary nutrients in Wag Harma and North Wello zones in Amhara between 1 and 10 April.

## **Ukraine**

### **Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 21 April 2022)**

.....  
.....

#### **WHO & Regional Offices** [to 23 Apr 2022]

<https://www.who.int/news>

*News [Selected]*

22 April 2022

*Statement*

#### **WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator**

*[See Milestones above for detail]*

21 April 2022

*News release*

#### **Over 1 million African children protected by first malaria vaccine**

*[See Milestones above for detail]*

19 April 2022

*Statement*

#### **Delivering on the G20 Leaders commitment to build an equitable and effective Financial Intermediary Fund (FIF) for Pandemic Preparedness and Response (PPR)**

*[See Milestones above for detail]*

.....

#### **WHO Director General Speeches** [selected]

<https://www.who.int/director-general/speeches>

*Selected*

20 April 2022

*Speech*

#### **WHO Director-General's opening remarks at the Inaugural Session of Global Ayush Investment and Innovation Summit** – 20 April 2022

19 April 2022

*Speech*

#### **WHO Director-General's opening remarks at the ground-breaking ceremony for the WHO Global Centre for Traditional Medicine** – 19 April 2022

.....

#### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region**

:: [Democratic Republic of Congo declares new Ebola outbreak in Mbandaka](#)

Brazzaville/Kinshasa, 23 April 2022 – The health authorities in the Democratic Republic of the Congo today declared an outbreak of Ebola after a case was confirmed in Mbandaka, a city in the north-western Equateur Province. This is the third outbreak in the province since 2018...

:: 22 April 2022 [Angola bolsters fight against COVID-19 misinformation](#)

:: 19 April 2022 [How home-based care eased Rwanda's COVID-19 response](#)

### **WHO Region of the Americas PAHO**

:: 22 Apr 2022

[20th Vaccination Week in the Americas aims to vaccinate nearly 140 million people](#)

PAHO initiative is an opportunity to accelerate vaccination against COVID-19 and improve coverage rates for other vaccines that have declined over the past decade Washington, DC, April 22, 2022

(PAHO/WHO)- With the goal of accelerating vaccination against COVID-19 and closing coverage gaps against other vaccine-preventable diseases, countries and...

:: 20 Apr 2022

[Two-thirds of people in Latin America and the Caribbean now vaccinated against COVID-19](#)

But while some countries of the region have the highest coverage in the world, others lag behind. Washington D.C. 20 April 2022 (PAHO) – Over two-thirds of people in Latin America and the Caribbean have now received two doses of COVID-19 vaccine while some countries have yet to reach even half of their populations, said the Pan American Health...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

:: [Ukraine: People with chronic diseases face massive challenges in accessing health care, according to new WHO survey](#) 22-04-2022

:: [Q&A on COVID-19 therapeutics](#) 20-04-2022

:: [Preparing for the worst: training health workers to deal with casualty surges from the war in Ukraine](#) 19-04-2022

### **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

### **23 April 2022 | Multi-Country – Acute, severe hepatitis of unknown origin in children**

*Outbreak overview*

...As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas (Figure 1). Cases have been reported in the United Kingdom of Great Britain and Northern Ireland (the



United Kingdom) (114), Spain (13), Israel (12), the United States of America (9), Denmark (6), Ireland (<5), The Netherlands (4), Italy (4), Norway (2), France (2), Romania (1), and Belgium (1)...

.....

### **WHO Events**

<https://www.who.int/news-room/events/1>

*[Selected]*

#### **World Immunization Week**

World Immunization Week 2022 - Long Life for All

24 – 30 April 2022

#### **World Malaria Day 2022 - Harness innovation to reduce the malaria disease burden and save lives**

25 April 2022

#### **10th ACT-Accelerator Facilitation Council meeting**

26 April 2022 12:30 – 15:00 CET

.....

### **New WHO Publications**

<https://www.who.int/publications/i>

*Selected Titles*

22 April 2022

#### **5th virtual WHO infodemic management conference meeting report: steps towards measuring the burden of infodemics**

*Overview*

This report summarizes the themes emerging from wide-ranging discussions at the 5th WHO Infodemic Management Conference, which was virtually conducted in November 2021. This infodemic can very broadly be characterized as excess information including, but not limited to, false or misleading information, in digital and physical environments during an acute public health event. It has led to confusion, health-detrimental and/ or risk-taking behaviours, all of which have been compounded by higher levels of mistrust in health authorities and public health responses. While remaining a dynamic goal-post, the definition of what is an infodemic has been evolving with increasing degrees of precision, as leading experts concur. This Conference was squarely focused on this foundational issue.

22 April 2022

#### **Therapeutics and COVID-19: living guideline**

21 April 2022

#### **Report of the technical consultation on innovative clinical trial designs for evaluating new TB preventive...**

21 April 2022

#### **COVID-19 Vaccine Introduction and deployment Costing tool (CVIC tool)**

21 April 2022

[Emergency in Ukraine: external situation report #8, published 21 April 2022: reporting period: 14–20...](#)

20 April 2022

[Malaria Policy Advisory Group \(MPAG\) meeting \(March 2022\)](#)

20 April 2022

[Consolidated report of country success stories in mitigating the impact of the COVID-19 pandemic on TB...](#)

19 April 2022

[WHO global conference on communicating science during health emergencies, Geneva, Switzerland, 7–25 June 2021 \(virtual meeting\): meeting report](#)

*Overview*

The COVID-19 pandemic has highlighted how much science and evidence-based public health measures can affect people’s lives. Journalists, healthcare workers, religious leaders, teachers and others had to become science communicators to effectively fulfill their professional roles. At the same time, researchers were requested to communicate their results transparently and explain the underlying scientific processes. Recognizing the challenge and importance of making science accessible and understandable to all, World Health Organization (WHO) convened a global conference in June 2021 to learn from the public and over 60 experts about how to effectively communicate science during health emergencies. This report summarizes the outcomes of the conference and proposed actions for WHO and partners.

.....  
.....  
.....

**CDC/ACIP [U.S.]** [to 23 Apr 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

[\*\*CDC Statement on Masks in Public Transportation Settings\*\*](#)

Wednesday, April 20, 2022

[\*\*CDC Launches New Center for Forecasting and Outbreak Analytics\*\*](#)

Tuesday, April 19, 2022

*[See Perspectives above for detail]*

.....

**ACIP Meetings**

Next ACIP Meeting

***April 20, 2022***

Presentation Slides:

**Coronavirus Disease (COVID-19) Vaccines**

[Introduction pdf icon\[14 pages\]](#)

Dr. M Daley

[Updates on vaccine effectiveness of COVID-19 booster dose pdf icon\[21 pages\]](#)

Dr. R Link-Gelles

[Updates on safety of COVID-19 booster dose pdf icon\[47 pages\]](#)

Dr. N Klein, Dr. T Shimabukuro

[VaST assessment pdf icon\[9 pages\]](#)

Dr. K Talbot

[Updates to the EtR Framework: COVID-19 vaccine booster doses in adults  \$\geq 50\$  years of age and immunocompromised individuals pdf icon\[83 pages\]](#)

Dr. S Oliver

[CDC guidance for second COVID-19 booster dose pdf icon\[19 pages\]](#)

Dr. E Hall

[Framework for future COVID-19 doses and next steps pdf icon\[20 pages\]](#)

Dr. S Oliver

.....

### **MMWR Weekly: Current Volume (71) April 22 2022 / No. 16**

[PDF of this issue](#)

- [Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2020–21 School Year](#)
- [Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022](#)

.....

### **[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)**

*Approximately 25 announcements/reports/data summaries.*

:: 4/22/22 [EARLY RELEASE: Provisional COVID-19 Age-Adjusted Death Rates, by Race and Ethnicity — United States, 2020–2021](#)

.....

.....

**Africa CDC** [to 23 Apr 2022]

<http://www.africacdc.org/>

*News*

*No new digest content identified.*

.....

.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 23 Apr 2022]

<http://en.nhc.gov.cn/>

*News*

**[April 23: Daily briefing on novel coronavirus cases in China](#)**

On April 22, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 2,988 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 23 Apr 2022]

<http://english.nmpa.gov.cn/>

*News*

**[Chinese mainland reports 2,119 new local confirmed COVID-19 cases, 1,931 in Shanghai](#)**

2022-04-22

The Chinese mainland Thursday reported 2,119 locally-transmitted confirmed COVID-19 cases, of which 1,931 were in Shanghai, according to the National Health Commission's report Friday.

**[More than 3.32b COVID-19 vaccine doses administered on the Chinese mainland](#)**

2022-04-22

More than 3.32 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

**[CCDC Weekly Reports: Current Volume \(4\)](#)**

2022-04-22 / No. 16 *ENVIRONMENTAL HEALTH ISSUE*

[PDF of this issue](#)

Recommendations: Recommendations of Controlling and Preventing Acute Health Risks of Fine Particulate Matter Pollution — China, 2021

Preplanned Studies: Effects of Cold Spells on Mortality — Ningbo City, Zhejiang Province, China, 2014–2018

Methods and Applications: Preliminary Study of Pulsed Ultraviolet Technology for Low-Temperature Disinfection

.....

***Contents [click to move among sections]***

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

.....

***Organization Announcements***

*Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Airfinity** [to 23 Apr 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS  
No new digest content identified.

**Paul G. Allen Frontiers Group** [to 23 Apr 2022]

<https://alleninstitute.org/news-press/>

News

**[Why is the human brain so difficult to understand? We asked 4 neuroscientists.](#)**

April 21, 2022

Thoughts, memories, sensations — why are we still in the dark about how they work?

**BMGF - Gates Foundation** [to 23 Apr 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

**Bill & Melinda Gates Medical Research Institute** [to 23 Apr 2022]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*  
No new digest content identified.

**CARB-X** [to 23 Apr 2022]

<https://carb-x.org/>

News

No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 23 Apr 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Informed Consent: A Monthly Review – April 2022](#)** is now posted [here](#)

:: **[Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)**

:: **[Patients, Politics, Pressure :: Pharma Stays Steady \[Mostly\] In Russia Sanctions Context Observations at 30 March 2022](#)** David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 23 Apr 2022]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 23 Apr 2022]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 23 Apr 2022]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 23 Apr 2022]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 23 Apr 2022]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 23 Apr 2022]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 23 Apr 2022]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*New Resources*

*No new digest content identified.*

**Fondation Merieux** [to 23 Apr 2022]

<http://www.fondation-merieux.org/>

*News, Events*

*Mérieux Foundation & University of Geneva co-organized event*

**22nd Advanced Vaccinology Course (ADVAC)**

May 9 - 20, 2022 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)

**Gavi** [to 23 Apr 2022]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GHIT Fund** [to 23 Apr 2022]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 23 Apr 2022]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 23 Apr 2022]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified*

**Hilleman Laboratories** [to 23 Apr 2022]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified*

**HHMI - Howard Hughes Medical Institute** [to 23 Apr 2022]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Vaccines Project** [to 23 Apr 2022]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 23 Apr 2022]

<https://www.iavi.org/>

*Latest News*

*No new digest content identified.*

**ICRC** [to 23 Apr 2022]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

**[ICRC Moscow Delegation: in brief](#)**

The delegation is one of our key humanitarian diplomacy hubs around the world, building dialogue with the Russian authorities, academic and expert circles, and other influential people and organizations in order to support our mission to protect and as

18-04-2022 | Publication

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 23 Apr 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

**[Americas: IFRC urges governments to save migrants' lives at High Level Regional Meeting on Migration](#)**

20/04/2022 | Press release

IFRC urges governments to save migrants' lives, ensure their access to essential services and social inclusion mechanisms, and scale up support to persons at risk of displacement related to disasters and the climate crisis...

**Institut Pasteur** [to 23 Apr 2022]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press release*

20.04.2022



**[When severe infection causes long-term mood disorders: A promising avenue to prevent mental illness following a transient infection](#)**

The brain is able to detect and regulate localized or systemic inflammation by using two communication pathways.

**IOM / International Organization for Migration** [to 23 Apr 2022]

<http://www.iom.int/press-room/press-releases>

*News - Selected*

*News*

22 Apr 2022

**[Almost 1 Million War Displaced to Benefit from IOM Ukraine Shelter Rehabilitation Programme](#)**

*News*

21 Apr 2022

**[One in Six People Internally Displaced in Ukraine](#)**

*News*

19 Apr 2022

**[Ukraine: Remarks by IOM Director General, António Vitorino, at the UN Security Council](#)**

**ISC / International Science Council** [to 23 Apr 2022]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News Blogs Podcasts Events*

*News Press releases*

**[International science organizations unite in support of at-risk, displaced and refugee scientists](#)**

20.04.2022

*Join the advocacy campaign to support at-risk, displaced and refugee scientists by signing the Science in Exile Declaration.*

**IVAC** [to 23 Apr 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

**[World Immunization Week 2022: Webinars](#)**

April 2022

During World Immunization Week 2022 the International Vaccine Access Center, along with global immunization and indigenous health partners, will host a three webinars. Registration is free, and we encourage all to sign up and save these dates on their calendars. Enabling Equitable Access to COVID-19 Vaccines for Indigenous Populations When: April 26, 2022 from 6:00 [...]

**IVI** [to 23 Apr 2022]

<http://www.ivi.int/>

*IVI News & Announcements*

**[International Vaccine Institute appoints two members to its Board of Trustees representing Ecuador and Rwanda](#)**

April 20, 2022 – SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with the mission to discover, develop and deliver safe, effective and affordable vaccines for global health, announced today that Dr. Ximena Garzón Villalba, Minister of Public Health of Ecuador, and Dr. Leon Mutesa, Professor of Human Genetics at the University of Rwanda, will join its Board of Trustees (BOT), representing Ecuador and Rwanda, respectively, two member states of IVI. Their terms will commence at the next BOT meeting scheduled for May 19-20, 2022, in Stockholm, Sweden...

**Johns Hopkins Center for Health Security** [to 23 Apr 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 23 Apr 2022]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*No new digest content identified.*

**National Academy of Medicine** - USA [to 23 Apr 2022]

<https://nam.edu/programs/>

*News [Selected]*

**[NAM Statement on the Importance of Ensuring a Systems-Based Approach to Patient Safety and Quality](#)**

April 19, 2022

The recent case of a former nurse who was found guilty of negligent homicide after the death of a patient due to a medication error prompts the need to underscore the recommendations from To Err is Human: Building a Safer Health System. A core finding of To Err is Human is that medical errors are most often caused by failures [...]

**[New National Academy of Medicine Consensus Study Launched on Improving Cross-Sectoral, Coordinated, and Equitable Governance of Emerging Technologies in Health and Medicine](#)**

April 15, 2022

An ad hoc committee under the auspices of the National Academies of Sciences, Engineering, and Medicine has been convened to develop a cross-sectoral governance framework for considering the potential benefits and risks that emerging science, technology, and innovation in health and medicine can bring to society. The framework will translate key ethics principles into the [...]

**National Academy of Sciences** - USA [to 23 Apr 2022]

<http://www.nasonline.org/news-and-multimedia/>

*News*

**[American Chemical Society Joins U.S. National Academy of Sciences in Effort to Support Researchers Forced to Flee Ukraine](#)**

April 20, 2022

With a 500000 donation the American Chemical Society has joined the U.S. National Academy of Sciences in an effort to help researchers who are being forced to flee Ukraine because of Russia's invasion.

**National Vaccine Program Office** - U.S. HHS [to 23 Apr 2022]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 23 Apr 2022]

<http://www.nih.gov/>

*News Releases*

**[Virtual Meeting and Listening Session on Oversight Framework for Research Involving Enhanced Potential Pandemic Pathogens](#)**

April 21, 2022 — Input from this listening session will help inform the deliberations and policy recommendations of the National Science Advisory Board for Biosecurity related to its current charge.

**OECD** [to 23 Apr 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

*Newsroom/Library*

*No new digest content identified.*

**PATH** [to 23 Apr 2022]

<https://www.path.org/media-center/>

*Press Releases*

**[PATH announces Dr. Fredrick Were as Vice Chair of the Board of Directors](#)**

April 21, 2022 by PATH

PATH is pleased to announce Dr. Fredrick Namenya Were, MD, MMed, PhD as Vice Chair of the board of directors. Dr. Were brings a unique mix of policy, research, and clinical experience to the leadership role. He has served on the board since March 2021 and is a member of the Governance, Impact, and Responsibility Committee...

**[PATH welcomes US\\$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi](#)**

April 19, 2022 by PATH

Seattle, April 19, 2022—PATH today welcomed a grant of close to US\$ 5 million to enable expanded introduction of the RTS,S/AS01 (RTS,S) malaria vaccine through the pilot program currently underway in areas of Ghana, Kenya, and Malawi. The grant would support use of RTS,S in pilot areas that have not yet received the vaccine.

The grant to PATH was recommended by [GiveWell](#), a US-based non-profit, for funding by [Open Philanthropy](#), also based in the United States. The award will provide each pilot country with funds to plan for and implement the expansion of malaria vaccination through the end of 2023, the formal end of the pilot program. The grant also will allow PATH and the World Health Organization (WHO) to provide technical assistance to the countries. The vaccine doses for the expansion into the (currently) non-vaccinating pilot areas are part of GSK's donation of up to 10 million doses for use in the pilot program...

**Sabin Vaccine Institute** [to 23 Apr 2022]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 23 Apr 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

22 April 2022

[Sustaining HIV services for people who use drugs in Odesa](#)

21 April 2022

[Welcoming Ukrainian refugees in Germany: big test for all](#)

20 April 2022

[Social entrepreneurship—a tool of self-empowerment for the LGBTI community](#)

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 23 Apr 2022]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

*No new digest content identified.*

**UNICEF** [to 23 Apr 2022]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*Press release*

04/22/2022

[At least 10 million children face severe drought in the Horn of Africa – UNICEF](#)

<https://www.unicef.org/press-releases/least-10-million-children-face-severe-drought-horn-africa-unicef>  
NAIROBI, 22 April 2022 – The number of children facing severe drought conditions across the Horn of Africa has increased by more than 40 per cent in the space of two months, warns UNICEF. Between February and April, the number of children facing the impact of drought including acute hunger, malnutrition and thirst increased from 7.25 million to...

*Press release*

04/21/2022

### **[Child immunization programme reaches Rohingya refugee children on Bhasan Char island](https://www.unicef.org/press-releases/child-immunization-programme-reaches-rohingya-refugee-children-bhasan-char-island)**

<https://www.unicef.org/press-releases/child-immunization-programme-reaches-rohingya-refugee-children-bhasan-char-island>

DHAKA, 21 April 2022 – This week, Rohingya refugee children on Bhasan Char in Bangladesh are receiving vaccinations through a routine childhood immunization programme. UNICEF provides technical and financial assistance to the Government of Bangladesh in support of childhood immunizations on Bhasan Char. While Rohingya refugee children have...

*[See Perspectives above for detail]*

*Press release*

04/20/2022

### **[Lebanon's crisis threatening children's health](https://www.unicef.org/press-releases/lebanons-crisis-threatening-childrens-health)**

<https://www.unicef.org/press-releases/lebanons-crisis-threatening-childrens-health>

BEIRUT, 20 April 2022 – The ripple effects of the global economic situation – with heightened prices and increased inflation – are exacerbating Lebanon's calamitous crisis, with grave consequences for children's health, UNICEF said in a report released to coincide with World Immunization Week (WIW). This will cause more disruptions in the health...

*Statement*

04/19/2022

### **[Statement by UNICEF Executive Director Catherine Russell on attacks against schools in Kabul, Afghanistan](https://www.unicef.org/press-releases/statement-unicef-executive-director-catherine-russell-attacks-against-schools-kabul)**

<https://www.unicef.org/press-releases/statement-unicef-executive-director-catherine-russell-attacks-against-schools-kabul>

NEW YORK, 19 April 2022 – "I am horrified by the brutal attacks targeting school children today in western Kabul, Afghanistan. The coordinated blasts occurred at the Mumtaz Tuition Center and Abdul Raheem Shaheed High School. "Reports are still being verified, but at least nine children are believed to have been killed and more than fifty injured..."

*Press release*

04/18/2022

### **[Sana'a authorities in Yemen sign action plan with UN to prevent grave violations against children](https://www.unicef.org/press-releases/sanaa-authorities-yemen-sign-action-plan-un-prevent-grave-violations-against-children)**

<https://www.unicef.org/press-releases/sanaa-authorities-yemen-sign-action-plan-un-prevent-grave-violations-against-children>

SANA'A, 18 April 2022 – Today Sana'a authorities signed an Action Plan with the United Nations to protect children and prevent grave violations against them in the context of the armed conflict in Yemen. The Action Plan commits the Sana'a authorities and their forces to comply with the prohibition of the recruitment and use of all children in...

**Unitaid** [to 23 Apr 2022]

<https://unitaid.org/>

*Featured News*

22 April 2022

### **[World Malaria Day: Unitaid drives forward equitable access to innovation to reduce the burden of malaria](#)**

**Vaccine Equity Cooperative [nee Initiative]** [to 23 Apr 2022]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative (Sabin)** [to 23 Apr 2022]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*Blog*

**[Keeping Vaccination in the Conversation](#)**

April 18, 2022

by: [Meredith Dockery](#), [Nick Boehman](#), [Abigail Quinn](#)

**Vaccine Confidence Project** [to 23 Apr 2022]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 23 Apr 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 23 Apr 2022]

<https://wellcome.ac.uk/news>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 23 Apr 2022]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 23 Apr 2022]

<https://www.wfpha.org/>

*Latest News - Blog*

*No new digest content identified.*

**World Bank** [to 23 Apr 2022]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

**EVENT: Scaling up Vaccine Deployment**

As global vaccine supplies increase, a key challenge is to ensure that supplies quickly get to where they are needed and, once they are there, countries have the capabilities and resources to get vaccines...

Date: April 28, 2022 Type: Feature Story

**World Customs Organization – WCO** [to 23 Apr 2022]

<http://www.wcoomd.org/>

*Latest News*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 23 Apr 2022]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

**Prevention is better than a cure: delivering quality vaccines to stop the spread of animal diseases**

20 April 2022

**WTO - World Trade Organisation** [to 23 Apr 2022]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events [Selected]*

**Multilateralism “must be reimaged and fit for purpose,” DG tells Brazilian diplomats**

18 April 2022

Brazil, and in particular its powerhouse agri-food sector, has benefited from open markets provided by the multilateral trading system, and it can benefit even more with a revitalized WTO, Director-General Ngozi Okonjo-Iweala told young diplomats and other guests at a lecture at Instituto Rio Branco, Brazil’s diplomatic academy, in Brasilia on 18 April. She stressed that multilateralism “must be reimaged and made fit for purpose to serve 21st century challenges”. The lecture opened a two-day visit for talks with government officials, the agriculture industry, parliamentarians and businesspeople. Her remarks are below.

*Speech*

.....

**ARM [Alliance for Regenerative Medicine]** [to 23 Apr 2022]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 23 Apr 2022]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 23 Apr 2022]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 23 Apr 2022]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 23 Apr 2022]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**[Joint Guidance on Virtual and Hybrid International Medical Congresses](#)**

13 April 2022

Joint Guidance on Virtual and Hybrid International Medical Congresses by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA)

:: [Joint Guidance on Virtual and Hybrid International Medical Congresses \(April 2022\)](#)

:: [Joint Guidance on Virtual and Hybrid International Medical Congresses \(April 2022\) Q&A](#)

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**International Alliance of Patients' Organizations – IAPO** [to 23 Apr 2022]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest content identified.*

**PhRMA** [to 23 Apr 2022]

<http://www.phrma.org/>

*Latest News [Selected]*

*No new digest content identified.*

\*

\*

\*

\*

***Contents [click to move among sections]***

:: [Coronavirus \[COVID-19\] - WHO](#)



:: Organization Announcements

:: Journal Watch

\* \* \* \*

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 24, Number 4: E249-341 Apr 2022

<https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities>

#### ***Health Equity in US Latinx Communities***

Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

### **American Journal of Infection Control**

April 2022 Volume 50 Issue 4 p367-476

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

April 2022 Volume 62 Issue 4 p473-660

<https://www.ajpmonline.org/current>

[Reviewed earlier]

## **American Journal of Public Health**

April 2022 112(52)

<http://ajph.aphapublications.org/toc/ajph/current>

**Supplement 2 2022 = Global Opioid Crisis**

## **American Journal of Tropical Medicine and Hygiene**

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

[Reviewed earlier]

## **Annals of Internal Medicine**

April 2022 Volume 175, Issue 4

<http://annals.org/aim/issue>

*Original Research*

### **[Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States - A Cost-Effectiveness Analysis](#)**

Anne M. Neilan, MD, MPH, Raphael J. Landovitz, MD, MSc, Mylinh H. Le, BA, [... et al.](#)

Pages:479–489

### **[Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021](#)**

FREE

Isaac See, MD, Allison Lale, MD, MPH, Paige Marquez, MSPH, Michael B. Streiff, MD, [... et al.](#)

Pages:513–522

### **[Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain](#)**

FREE

Kaspar Staub, PhD, Radoslaw Panczak, PhD, Katarina L. Matthes, PhD, Joël Floris, PhD, [... et al.](#)

Pages:523–532

### **[Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 \(Delta\) Variant During an Outbreak in Guangdong, China - A Cohort Study](#)**

FREE

Min Kang, MMed, Yao Yi, MMed, Yan Li, PhD, Limei Sun, BM, Aiping Deng, MMed, Ting Hu, MMed, [... et al.](#)

Pages:533–540

### **[Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel - A Retrospective Cohort Study](#)**

FREE

Anders Hviid, DrMedSci, Jørgen Vinsløv Hansen, PhD, Emilia Myrup Thiesson, MSc, [... et al.](#)

*Reviews*

**[Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection](#)**

FREE

Mark Helfand, MD, MPH, Clia Fiordalisi, MS, Jack Wiedrick, MS, Katrina L. Ramsey, MPH, [... et al.](#)

**Artificial Intelligence – An International Journal**

Volume 305 April 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/305/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 23 Apr 2022)

[No new digest content identified]

**BMJ Global Health**

April 2022 - Volume 7 - 4

<https://gh.bmj.com/content/7/4>

[Reviewed earlier]

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 23 Apr 2022)

**[Coverage, inequity and predictors of hepatitis B birth vaccination in Myanmar from 2011–2016: results from a national survey](#)**

*Hepatitis B virus birth dose (HepB-BD) vaccination is recommended to reduce mother to infant transmission. We evaluated the HepB-BD status of women who gave birth between 2011 and 2016 (N = 3,583) using the 2015–...*

Authors: August C. T. Anderson, Adam Richards, Kevin Delucchi and Mandana Khalili

Citation: BMC Health Services Research 2022 22:516

Content type: Research Published on: 19 April 2022

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 23 Apr 2022)

**[Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe](#)**

*In sub-Saharan Africa, adolescent girls and young women (AGYW) are at high risk of acquiring HIV. A growing number of sub-Saharan African countries are beginning to avail pre-exposure prophylaxis, or PrEP, but...*

Authors: Morten Skovdal, Phyllis Magoge-Mandizvidza, Freedom Dzatatira, Rufurwokuda Maswera, Constance Nyamukapa, Ranjeeta Thomas, Owen Mugurungi and Simon Gregson

Citation: BMC Infectious Diseases 2022 22:399  
Content type: Research Published on: 23 April 2022

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 23 Apr 2022)

#### **[Ethical considerations around volunteer payments in a malaria human infection study in Kenya: an embedded empirical ethics study](#)**

*Human Infection Studies (HIS) have emerged as an important research approach with the potential to fast track the global development of vaccines and treatments for infectious diseases, including in low resourc...*

Authors: Primus Che Chi, Esther Awuor Owino, Irene Jao, Philip Bejon, Melissa Kapulu, Vicki Marsh and Dorcas Kamuya

Citation: BMC Medical Ethics 2022 23:46

Content type: Research Published on: 20 April 2022

#### **[Participant recall and understandings of information on biobanking and future genomic research: experiences from a multi-disease community-based health screening and biobank platform in rural South Africa](#)**

*Limited research has been conducted on explanations and understandings of biobanking for future genomic research in African contexts with low literacy and limited healthcare access. We report on the findings o...*

Authors: Manono Luthuli, Nothando Ngwenya, Dumsani Gumede, Resign Gunda, Dickman Gareta, Olivier Koole, Mark J. Siedner, Emily B. Wong and Janet Seeley

Citation: BMC Medical Ethics 2022 23:43

Content type: Research Published on: 18 April 2022

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 23 Apr 2022)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 23 Apr 2022)

#### **[Knowledge, attitudes, and practices related to the COVID-19 pandemic among pregnant women in Bangkok, Thailand](#)**

*Pregnancy is associated with increased risk for severe COVID-19. Few studies have examined knowledge, attitudes, and practices (KAP) related to pregnancy during the pandemic. This study investigated the associ...*

Authors: Jadsada Kunno, Pataraporn Yubonpunt, Busaba Supawattanabodee, Chavanant Sumanasrethakul and Budsaba Wiriyasirivaj

Citation: BMC Pregnancy and Childbirth 2022 22:357

Content type: Research Published on: 23 April 2022

## **BMC Public Health**

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 23 Apr 2022)

### **[From science to politics: COVID-19 information fatigue on YouTube](#)**

*The COVID-19 pandemic is the first pandemic where social media platforms relayed information on a large scale, enabling an "infodemic" of conflicting information which undermined the global response to the pan...*

Authors: Chyun-Fung Shi, Matthew C. So, Sophie Stelmach, Arielle Earn, David J. D. Earn and Jonathan Dushoff

Citation: BMC Public Health 2022 22:816

Content type: Research Published on: 23 April 2022

### **[Evaluating the effectiveness of Hong Kong's border restriction policy in reducing COVID-19 infections](#)**

*This study evaluates the effectiveness of Hong Kong's strict border restrictions with mainland China in curbing the transmission of COVID-19. Combining big data from Baidu Population Migration with traditional...*

Authors: Pengyu ZHU and Xinying TAN

Citation: BMC Public Health 2022 22:803

Content type: Research Published on: 21 April 2022

### **[Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model](#)**

*Human papillomavirus (HPV) vaccines have been proven effective against cervical cancer. However, HPV vaccination is not included in the Chinese immunization program. This study aimed to assess the cost-effecti...*

Authors: Liangru Zhou, Baiyang Gu, Jian Wang, Guoxiang Liu and Xin Zhang

Citation: BMC Public Health 2022 22:777

Content type: Research article Published on: 18 April 2022

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 23 Apr 2022)

[No new digest content identified]

## **BMJ Evidence-Based Medicine**

April 2022 - Volume 27 - 2

<https://ebm.bmj.com/content/27/2>

[Reviewed earlier]

## **BMJ Open**

April 2022 - Volume 12 - 4

<https://bmjopen.bmj.com/content/12/4>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 100(4); 2022 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/404046/>

[Reviewed earlier]

### **Cell**

Apr 14, 2022 Volume 185 Issue 8 p1261-1444

<https://www.cell.com/cell/current>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 48, Issue 3 Pages: 359-511 May 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 111, Issue 4 Pages: 705-971 April 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

#### ***Therapeutic Innovations in Neuroscience***

The theme of this issue of *Clinical Pharmacology & Therapeutics* (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

### **Clinical Therapeutics**

March 2022 Volume 44 Issue 3 p349-472

<http://www.clinicaltherapeutics.com/current>

*Original Research*

#### **[Rolling Reviews During COVID-19: The European Union Experience in a Global Context](#)**

Roelie Marinus, Sarah Mofid, Marya Mpandzou, Thomas C. Kühler

Published online: January 09, 2022

p352-363

Open Access

*Reviews*

#### **[Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World](#)**

Leah Burns, Nadege Le Roux, Robert Kalesnik-Orszulak,...Mathias Hukkelhoven, Frank Rockhold, John O'Donnell

Published online: February 15, 2022

p420-437  
Open Access

*Commentaries*

**[Beyond Influenza Vaccination: Expanding Infrastructure for Hospital-based Pediatric COVID-19 Vaccine Delivery](#)**

Annika M. Hofstetter, Suchitra Rao, Ravi Jhaveri  
Published online: January 26, 2022  
p450-455

**Clinical Trials**

Volume 19 Issue 2, April 2022  
<https://journals.sagepub.com/toc/ctja/19/2>  
[New issue; No digest content identified]

**Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 23 Apr 2022]  
[No new digest content identified]

**Contemporary Clinical Trials**

Volume 114 March 2022  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/114/suppl/C>  
[Reviewed earlier]

**The CRISPR Journal**

Volume 5, Issue 2 / April 2022  
<https://www.liebertpub.com/toc/crispr/5/2>  
[New issue; No digest content identified]

**Current Genetic Medicine Reports**

Volume 9, issue 4, December 2021  
<https://link.springer.com/journal/40142/volumes-and-issues/9-4>  
[Reviewed earlier]

**Current Opinion in Infectious Diseases**

April 2022 - Volume 35 - Issue 2  
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>  
[Reviewed earlier]

**Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 22, Issue 1 Pages: 1-62 March 2022

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 32, Issue 1, 2022

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 46, Issue 2 Pages: 299-586 April 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

### **EMBO Reports**

Volume 23 Issue 4 5 April 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 28, Number 4—April 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 38 March 2022

<https://www.sciencedirect.com/journal/epidemics/vol/38/suppl/C>

[Reviewed earlier]



## **Epidemiology and Infection**

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 44, Issue 2 Pages: 1-40 March–April 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception***

[Reviewed earlier]

## **Ethics & International Affairs**

Winter 2021 (35.4) | December 2021

<https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/>

*TABLE OF CONTENTS*

[Reviewed earlier]

## **Ethics, Medicine and Public Health**

Volume 21 (April 2022)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/21/suppl/C>

[New issue; No digest content identified]

## **The European Journal of Public Health**

Volume 32, Issue 2, April 2022

<https://academic.oup.com/eurpub/issue/32/2>

[Reviewed earlier]

## **Expert Review of Vaccines**

Vol 21 (4) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Forum for Development Studies**

Volume 49, 2022 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 23 Apr 2022]

**[Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study](#)**

*Breast milk is a vehicle to transfer protective antibodies from the lactating mother to the neonate. After SARS-CoV-2 infection, virus-specific IgA and IgG have been identified in breast milk, however, there a...*

Authors: Marta Selma-Royo, Christine Bäuerl, Desirée Mena-Tudela, Laia Aguilar-Camprubí, Francisco J. Pérez-Cano, Anna Parra-Llorca, Carles Lerin, Cecilia Martínez-Costa and Maria Carmen Collado

Citation: Genome Medicine 2022 14:42

Content type: Research Published on: 21 April 2022

**Global Health Action**

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 10, No. 1 February 28, 2022

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 23 Apr 2022]

[No new digest content identified]

**Global Public Health**

Volume 17, Issue 4 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 23 Apr 2022]

[No new digest content identified]

**Health and Human Rights**

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

**Health Economics, Policy and Law**

Volume 17 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 37, Issue 3, March 2022

<https://academic.oup.com/heapol/issue/37/3>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 23 Apr 2022]

[No new digest content identified]

### **Human Gene Therapy**

Volume 33, Issue 5-6 / March 2022

<https://www.liebertpub.com/toc/hum/33/5-6>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Online Article*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 18, Issue 1, 2022

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Immunity**

Apr 12, 2022 Volume 55 Issue 4 p575-734

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 23 Apr 2022]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 23 Apr 2022]

**[Priorities of China's participation in global malaria elimination: the perspective of malaria endemic countries](#)**

*Malaria is one of the major diseases affecting global health, while progress in malaria control and elimination has stagnated in some endemic countries. China has been certificated malaria free by World Health...*

Authors: Yan Xie, Jie Wang, Yinuo Sun, Xuedan Ke, Zheng Xie, Jun Cao and Yangmu Huang

Citation: Infectious Diseases of Poverty 2022 11:46

Content type: Research Article Published on: 20 April 2022

**[Prompt and precise identification of various sources of infection in response to the prevention of malaria re-establishment in China](#)**

*Prompt and precise diagnosis of patients is an essential component of malaria control and elimination strategies, it is even more vital for the prevention of malaria re-establishment in the post elimination ph...*

Authors: Jianhai Yin, He Yan and Mei Li

Citation: Infectious Diseases of Poverty 2022 11:45

Content type: Commentary Published on: 18 April 2022

**International Health**

Volume 14, Issue 2, March 2022

<https://academic.oup.com/inthealth/issue/14/2>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 9, No 4 (2022) April 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/87>

[New issue; No digest content identified]

**International Journal of Epidemiology**

Volume 51, Issue 1, February 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 15 Issue 2, 2022

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/2>

*Table of Contents*

**[The role of social media in promoting citizenship values of international students during the COVID-19 global health crisis](#)**

Thelal Iqab Oweis

The purpose of this study, accordingly, is to not only offer insights about Arab international students' stress management and adjustment mechanisms while abroad but also bring to light the extent to which these digital citizens' use of social media networks reinforces their citizenship values and preserves their national identity during the COVID-19 global health crisis.

**JAMA**

April 19, 2022, Vol 327, No. 15, Pages 1421-1514

<https://jamanetwork.com/journals/jama/currentissue>

*Original Investigation*

**[Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes](#)**

Maria C. Magnus, PhD; Anne K. Örtqvist, MD, PhD; Elisabeth Dahlqvist, PhD; et al.

free access

JAMA. 2022;327(15):1469-1477. doi:10.1001/jama.2022.3271

This cohort study examines the risk of adverse pregnancy outcomes after vaccination against SARS-CoV-2 during pregnancy based on registry data from Sweden and Norway.

*Editorial*

**[COVID-19 mRNA Vaccines During Pregnancy New Evidence to Help Address Vaccine Hesitancy](#)**

Elyse O. Kharbanda, MD, MPH; Gabriela Vazquez-Benitez, PhD

**[Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes](#)**

Deshayne B. Fell, PhD; Tavleen Dhinsa, MSc; Gillian D. Alton, PhD; et al.

free access

JAMA. 2022;327(15):1478-1487. doi:10.1001/jama.2022.4255

This population-based cohort study examines the association between COVID-19 vaccination during pregnancy and maternal and neonatal peripartum outcomes just before, during, or after delivery.

*Research Letter*

**[COVID-19 Cases and Disease Severity in Pregnancy and Neonatal Positivity Associated With Delta \(B.1.617.2\) and Omicron \(B.1.1.529\) Variant Predominance](#)**

Emily H. Adhikari, MD; Lorre MacDonald, CNM; Jeffrey A. SoRelle, MD; et al.

free access

JAMA. 2022;327(15):1500-1502. doi:10.1001/jama.2022.4356

This study examines infections, illness severity, vaccinations, and early neonatal infections among obstetric patients during the pre-Delta, Delta, and Omicron periods of the COVID-19 pandemic.

*Viewpoint*

**[Reducing "COVID-19 Misinformation" While Preserving Free Speech](#)**

William M. Sage, MD, JD; Y. Tony Yang, ScD, LLM, MPH

free access has audio

JAMA. 2022;327(15):1443-1444. doi:10.1001/jama.2022.4231

This Viewpoint discusses actions that health care leaders and policy makers can take to better assess the likely constitutionality of reducing “COVID misinformation” through government prohibitions or sanctions.

[Audio Author Interview](#): Reducing “COVID-19 Misinformation” While Preserving Free Speech

## **JAMA Network**

### **[COVID-19 Update April 23, 2022](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

## **JAMA Pediatrics**

April 2022, Vol 176, No. 4, Pages 335-428

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBI Evidence Synthesis**

March 2022 - Volume 20 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

## **Journal of Adolescent Health**

April 2022 Volume 70 Issue 4 p517-696

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

## **Journal of Community Health**

Volume 47, issue 2, April 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-2>

[Reviewed earlier]

## **Journal of Development Economics**

Volume 156 May 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/156/suppl/C>

[Reviewed earlier]

## **Journal of Empirical Research on Human Research Ethics**

Volume 17 Issue 1-2, February-April 2022  
<http://journals.sagepub.com/toc/jre/current>  
[Reviewed earlier]

**Journal of Epidemiology & Community Health**

April 2022 - Volume 76 - 4  
<https://jech.bmj.com/content/76/4>  
[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 15, Issue 1 Pages: 1-72 March 2022  
<https://onlinelibrary.wiley.com/toc/17565391/current>  
[Reviewed earlier]

**Journal of Global Ethics**

Volume 17, Issue 3, 2021  
<http://www.tandfonline.com/toc/rjge20/current>  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 33, Number 1, February 2022  
<https://muse.jhu.edu/issue/47329>  
*Table of Contents*  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 24, issue 2, April 2022  
<https://link.springer.com/journal/10903/volumes-and-issues/24-2>  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 20, 2022 \_ Issue 1  
<https://www.tandfonline.com/toc/wimm20/current>  
[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 225, Issue 4, 15 February 2022  
<https://academic.oup.com/jid/issue/225/4>  
[Reviewed earlier]

**Journal of Medical Ethics**

April 2022 - Volume 48 - 4

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 9, Issue 2 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

**Journal of Pediatrics**

April 2022 Volume 243 p1-246

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 23 Apr 2022]

[No new digest content identified]

**Journal of Public Health Management & Practice**

May/June 2022 - Volume 28 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 43, issue 1, March 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-1>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

April 2022 Volume 19 Issue 189

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]



## **Journal of Travel Medicine**

Volume 29, Issue 2, March 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

## **Journal of Virology**

Volume 96 • Number 7 • April 2022

<http://jvi.asm.org/content/current>

*Evolution Commentary* 16 March 2022

### **SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant**

Ben Berkhout, Elena Herrera-Carrillo

<https://doi.org/10.1128/jvi.00090-22>

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads rapidly and harbors many mutations in the spike protein, but the origin of this virus variant remains unclear. We address the role of unusual virus evolution ...

## **The Lancet**

Apr 23, 2022 Volume 399 Number 10335 p1573-1668, e38

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

### **Malaria in 2022: a year of opportunity**

The Lancet

The theme of this year's World Malaria Day, April 25, is "Harness innovation to reduce the malaria disease burden and save lives." WHO is calling for investment and innovation in vector control, diagnostics, and treatments to help countries eliminate malaria after several years of stalled progress. In 2015, the World Health Assembly adopted a strategy to guide efforts towards elimination. But the first milestone—to achieve a 40% global reduction in malaria mortality rate and case incidence by 2020—was missed. Funding for malaria control has levelled off. Malaria mortality and incidence rates have not changed appreciably since 2015. There were an estimated 627 000 malaria deaths and 241 million malaria cases in 2020 (a 12% and 7% increase, respectively, compared with 2015). Given the stagnation of recent years, what cause is there to hope for a real change now?

The devastating setbacks to malaria programmes resulting from the COVID-19 pandemic might prompt a pessimistic answer. In April, 2020, WHO projected a doubling of malaria deaths during the pandemic if no actions were taken. Major global health organisations working on malaria—led by the Global Fund, along with the RBM Partnership to End Malaria, and the US President's Malaria Initiative—put together the COVID-19 Response Mechanism, a massive effort to restructure resources and activities to avert the worst-case scenario. Still, there were 14 million more malaria cases and 69 000 more deaths in 2020 compared with 2019. An estimated 68% of the excess deaths were linked to service disruptions due to COVID-19. The pandemic diverted resources, overwhelmed health systems, and exacerbated inequalities, not only for malaria, but also for HIV and tuberculosis.

Even before COVID-19, concerns had been voiced about the slowed progress of malaria programmes. Nevertheless, in 2019 a Lancet Commission on malaria eradication reaffirmed that eradication—an ambitious permanent reduction of the global incidence to zero—is possible, worthwhile, affordable, and necessary. It recommended an immediate, firm commitment to malaria eradication, especially an

increase in funding and closer more strategic collaboration between major malaria organisations. And there have been some notable achievements. The WHO European region was certified malaria-free in 2016, as was Sri Lanka in 2016, Argentina in 2019, and China in 2021. However, 96% of the world's malaria cases and deaths each year occur in Africa; it is there that the success or failure will be decided.

Scientific advances are providing new tools for malaria control. RTS,S—the world's first effective malaria vaccine—was approved last year. Last month, The Lancet published results of a clinical trial showing the effectiveness of a new chlorfenapyr long-lasting insecticidal net that could help to mitigate the impact of insecticide resistance among mosquitoes. The roll-out of new interventions such as these is crucial to curtail malaria mortality, but it is not possible without funding.

In December, 2021, the Gavi board approved an initial investment for the procurement and delivery of RTS,S to sub-Saharan Africa. Later this year, the Global Fund will host its seventh replenishment meeting. It is asking for US\$18 billion to support its 2024–26 programmes for malaria, HIV, and tuberculosis, to strengthen health systems, and to reinforce pandemic preparedness. Modelling by the Global Fund predicts that, if it is fully funded, the malaria mortality rate would drop by 66% by 2026, and case incidence by 69%. By contrast, a counterfactual scenario of continued COVID-19 disruption would see a rapid and severe resurgence of malaria deaths and cases, resulting in an additional 2 million deaths and 654 million cases that could have been avoided. The replenishment scenario makes ambitious assumptions about the scale-up of malaria treatment and bednet distribution, as well as roll-out of the RTS,S vaccine. But the model presents countries and donors with a stark choice.

The case for commitment to investment and global collaboration for malaria is clear. Although COVID-19 has harmed malaria programmes and squeezed budgets, new technologies mean that 2022 is also a year of opportunity—if the opportunity is taken. To “harness innovation”, as WHO puts it, will require substantial funding support both domestically and from donors. It will also require meaningful policy commitments from countries to reaffirm the idea of ceasing mortality and morbidity due to malaria. The UN Sustainable Development Goal of ending malaria as a public health threat by 2030 is at stake, and, with it, the lives of hundreds of thousands of people each year.

#### *Articles*

[\*\*Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study\*\*](#)

Cristina Menni, et al.

Open Access

#### **The Lancet Child & Adolescent Health**

Apr 2022 Volume 6 Number 4 p215-278, e13-e15

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

#### **Lancet Digital Health**

Apr 2022 Volume 4 Number 4 e207-e289

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Apr 2022 Volume 10 Number 4 e448-e584

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Apr 2022 Volume 22 Number 4p 427-562, e101-e127

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Apr 2022 Volume 7 Number 4 e291-e390

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Apr 2022 Volume 10 Number 4 p313-420, e34-e43

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 26, issue 5, May 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-5>

[New issue; No digest content identified]

### **Medical Decision Making (MDM)**

Volume 42 Issue 3, April 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 100, Issue 1 Pages: 1-313 March 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Nature**

Volume 604 Issue 7906, 21 April 2022

<https://www.nature.com/nature/volumes/604/issues/7906>

*Perspective* | 20 April 2022

### **[The Human Pangenome Project: a global resource to map genomic diversity](#)**

The Human Pangenome Reference Consortium aims to offer the highest quality and most complete human pangenome reference that provides diverse genomic representation across human populations. Ting Wang, Lucinda Antonacci-Fulton, David Haussler

*Article* | 03 March 2022 | Open Access

### **[Antibody evasion properties of SARS-CoV-2 Omicron sublineages](#)**

A study reports on the antigenic characterization of SARS-CoV-2 BA.1, BA.1.1 and BA.2 and the neutralizing activity of different monoclonal antibodies and sera against them.

Sho Iketani, Lihong Liu, David D. Ho

## **Nature Biotechnology**

Volume 40 Issue 4, April 2022

<https://www.nature.com/nbt/volumes/40/issues/4>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 23 Apr 2022)

[No new digest content identified]

## **Nature Genetics**

Volume 54 Issue 4, April 2022

<https://www.nature.com/ng/volumes/54/issues/4>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 6 Issue 3, March 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/3>

[Reviewed earlier]

## **Nature Medicine**

Volume 28 Issue 4, April 2022

<https://www.nature.com/nm/volumes/28/issues/4>

### ***The future of cancer research***

This special Focus issue presents an overview of the most promising developments in cancer research, with an eye toward delivering research and care that is innovative, equitable, sustainable and patient-focused. The cover presents an artistic rendition of the study by Seliger and colleagues, in this issue, showing an increased risk of death by suicide in patients with cancer and underscoring the need for comprehensive psycho-oncological therapy during routine clinical practice to improve the quality of life of such patients.

Article / 14 January 2022 | Open Access

**[Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England](#)**

A test-negative case–control analysis of data from the National Immunisation Management System in England demonstrates significant levels of increased protection against hospitalization or death from COVID with mRNA booster vaccines following a primary two-dose course of either ChAdOx1-S or BNT162b2 vaccines.

Nick Andrews, Julia Stowe, Jamie Lopez Bernal

Article | 09 February 2022 | Open Access

**[Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil](#)**

A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.

Thiago Cerqueira-Silva, Srinivasa Vittal Katikireddi, Viviane S. Boaventura

**Nature Reviews Genetics**

Volume 23 Issue 4, April 2022

<https://www.nature.com/nrg/volumes/23/issues/4>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 22 Issue 4, April 2022

<https://www.nature.com/nri/volumes/22/issues/4>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 21 Issue 4, April 2022

<https://www.nature.com/nrd/volumes/21/issues/4>

[Reviewed earlier]

**New England Journal of Medicine**

April 21, 2022 Vol. 386 No. 16

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Not Ready for the End Game — Why Ending Federal Covid-19 Emergency Declarations Will Harm Access to Care](#)**

J.R. Horwitz and L.F. Wiley

*Original Articles*

**[Covid-19 Vaccine Effectiveness against the Omicron \(B.1.1.529\) Variant](#)**

N. Andrews and Others

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 23 Apr 2022]

*Article*

[No new digest content identified]

### **Pediatrics**

Volume 149, Issue 4, April 1, 2022

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 40, issue 3, March 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-3>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 23 Apr 2022)

[\*\*One step closer to a transmissible vaccine for rabies virus\*\*](#)

Scott L. Nuismer

*Primer* | published 20 Apr 2022 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3001607>

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 23 Apr 2022)

[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 23 Apr 2022)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 23 Apr 2022)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 23 Apr 2022]

*Research Article*

**[Masks, money, and mandates: A national survey on efforts to increase COVID-19 vaccination intentions in the United States](#)**

Rikki H. Sargent, Shaelyn Laurie, Leah Moncada, Leo F. Weakland, James V. Lavery, Daniel A. Salmon, Walter A. Orenstein, Robert F. Breiman

Research Article | published 21 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0267154>

**[Assessment of COVID-19 vaccine hesitancy among Zimbabweans: A rapid national survey](#)**

Paddington Tinashe Mundagowa, Samantha Nokuthula Tozivepi, Edward Tafumaneyi Chiyaka, Fadzai Mukora-Mutseyekwa, Richard Makurumidze

Research Article | published 21 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266724>

**[The role of vaccination in a model of asset pricing during a pandemic](#)**

Yuta Saito

Research Article | published 21 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266511>

**[COVID-19 vaccination acceptance among dental students and dental practitioners: A systematic review and meta-analysis](#)**

Galvin Sim Siang Lin, Hern Yue Lee, Jia Zheng Leong, Mohammad Majduddin Sulaiman, Wan Feun Loo, Wen Wu Tan

Research Article | published 19 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0267354>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 23 Apr 2022]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

April 12, 2022 | vol. 119 | no. 15

<https://www.pnas.org/toc/pnas/119/15>

*Perspective* April 6, 2022 Coronavirus (COVID-19) Open Access

**[COVID-19 therapeutics: Challenges and directions for the future](#)**

The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the greatest medical emergency of the last century. COVID-19 has highlighted health disparities both within and between countries and will leave a lasting impact on global ...

Philip C. Robinson, David F. L. Liew, [...]Nicole Litzman

*Statistics*

*Research Article* April 8, 2022 Dataset Coronavirus (COVID-19)Open Access

## **[Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States](#)**

Short-term probabilistic forecasts of the trajectory of the COVID-19 pandemic in the United States have served as a visible and important communication channel between the scientific modeling community and both the general public and decision-makers. ...

[Estee Y. Cramer, Evan L. Ray, \[...\]Nicholas G. Reich](#)

## **Prehospital & Disaster Medicine**

Volume 37 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 157 April 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/157/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

13 April 2022 Volume 289 Issue 1972

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

## **Public Health**

Volume 205 Pages e1-e30, 1-216 (April 2022)

<https://www.sciencedirect.com/journal/public-health/vol/205/suppl/C>

[Reviewed earlier]

## **Public Health Ethics**

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Reports**

Volume 137 Issue 2, March/April 2022

<https://journals.sagepub.com/toc/phrg/137/2>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 32 Issue 4, March 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]



### **Research Ethics**

Volume 18 Issue 2, April 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 23 Apr 2022]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

[No new digest content identified]

### **Risk Analysis**

Volume 42, Issue 3 Pages: 429-655 March 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 23 Apr 2022]

[No new digest content identified]

### **Science**

Volume 376| Issue 6591| 22 Apr 2022

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science Translational Medicine**

Volume 14| Issue 641| 20 Apr 2022

<https://www.science.org/toc/stm/current>

*Research Articles*

[\*\*Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant\*\*](#)

BY Ai-ris Y. Collier, et al.

20 Apr 2022

Open Access

SARS-CoV-2 breakthrough infections led to robust serum and mucosal antibody responses and peripheral T cell responses in vaccinated individuals.

### **Social Science & Medicine**

Volume 294 February 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/294/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 23 Apr 2022]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 43, issue 1, February 2022

<https://link.springer.com/journal/11017/volumes-and-issues/43-1>

[New issue; No digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 46 March–April 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 27, Issue 4 Pages: i-iv, 337-465 April 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

*RESEARCH ARTICLES*

[\*\*COVID-19 vaccine acceptability among healthcare workers in Ethiopia: Do we practice what we preach?\*\*](#)

[Daniel Yilma](#), [Rezika Mohammed](#), [Seid Getahun Abdela](#), [Wendemagegn Enbiale](#), [Fasil Seifu](#), [Myrthe Pareyn](#), [Laurens Liesenborghs](#), [Johan van Griensven](#), [Saskia van Henten](#)

Pages: 418-425

First Published: 01 March 2022

### **Vaccine**

Volume 40, Issue 15 Pages 2241-2364 (1 April 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/15>

*Research article Abstract only*

[\*\*Attitudes of junior healthcare professionals towards mandatory vaccination\*\*](#)

[Ioanna Kakatsaki](#), [Eleni Vergadi](#), [Emmanouil Paraskakis](#), [Emmanouil Galanakis](#)

Pages 2247-2250

*Research article Open access*

**[Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination](#)**

Antonia Morga, Tomomi Kimura, Qi Feng, Nigel Rozario, Jason Schwartz  
Pages 2274-2281

*Research article Full text access*

**[The impact of COVID-19 on routine pediatric vaccination delivery in Brazil](#)**

Carolina Moura, Paul Truche, Lucas Sousa Salgado, Thiaro Meireles, ... David Mooney  
Pages 2292-2298

*Research article Open access*

**[Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine](#)**

Thomas McAndrew, Juan Cambeiro, Tamay Besiroglu  
Pages 2331-2341

Vaccine

Volume 40, Issue 14 Pages 2123-2240 (25 March 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/14>

*Discussion Full text access*

**[Supporting individual vaccine decision-making: A role for vaccination counselors](#)**

Angela K. Ulrich, Maria E. Sundaram, Nicole E. Basta  
Pages 2123-2125

*Discussion Full text access*

**[The scourge of vaccine falsification](#)**

Pierre Saliou, Quentin Duteil, Stanley A. Plotkin, Marc Gentilini  
Pages 2126-2128

*Review article Open access*

**[WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations](#)**

Jerome Amir Singh, Sonali Kochhar, Jonathan Wolff, Caesar Atuire, ... Ross E.G. Upshur  
Pages 2140-2149

*Research article Abstract only*

**[Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia](#)**

Abrham Wondimu, Maarten J. Postma, Marinus van Hulst  
Pages 2161-2167

*Research article Open access*

**[Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom](#)**

Vincent Daniels, Kunal Saxena, Oscar Patterson-Lomba, Andres Gomez-Lievano, ... Elamin Elbasha  
Pages 2173-2183

*Research article Full text access*

**[Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans](#)**

Feng Hao, Wanyun Shao  
Pages 2191-2201

*Research article Abstract only*

**[The impact of Facebook's vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis](#)**

Jiayan Gu, Avi Dor, Kun Li, David A. Broniatowski, ... Lorien C. Abroms  
Pages 2209-2214

*Research article Full text access*

**[Social media use and vaccine hesitancy in the European Union](#)**

Massimiliano Mascherini, Sanna Nivakoski  
Pages 2215-2225

*Research article Open access*

**[Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine](#)**

Fan Gao, Chaoqiang An, Lianlian Bian, Yiping Wang, ... Miao Xu  
Pages 2233-2239

**Value in Health**

April 2022 Volume 25 Issue 4 p473-676

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....  
.....

**[Pre-Print Servers](#)**

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

### **[Estimating the distribution of COVID-19-susceptible, -recovered, and -vaccinated individuals in Germany up to April 2022](#)**

Benjamin F Maier, Annika H Rose, Angelique Burdinski, Pascal Klamser, Hannelore Neuhauser, Ole Wichmann, Lars Schaade, Lothar H Wieler, Dirk Brockmann  
medRxiv 2022.04.19.22274030; doi: <https://doi.org/10.1101/2022.04.19.22274030>

### **[Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya](#)**

Stacey Orangi, John Ojal, Samuel P.C. Brand, Cameline Orlando, Angela Kairu, Rabia Aziza, Morris Ogero, Ambrose Agweyu, George M Warimwe, Sophie Uyoga, Edward Otieno, Lynette I Ochola-Oyier, Charles N Agoti, Kadondi Kasera, Patrick Amoth, Mercy Mwangangi, Rashid Aman, Wangari Ng'ang'a, Ifedayo M. O Adetifa, J Anthony G Scott, Philip Bejon, Matt J. Keeling, Stefan Flasche, D. James Nokes, Edwine Barasa  
medRxiv 2022.04.21.22274150; doi: <https://doi.org/10.1101/2022.04.21.22274150>

### **[Strengthening vaccination delivery system resilience in the context of protracted humanitarian crisis: a realist-informed systematic review](#)**

Sharif A Ismail, Sze Tung Lam, Sadie L Bell, Fouad M. Fouad, Karl Blanchet, Josephine Borghi  
medRxiv 2022.04.21.22273340; doi: <https://doi.org/10.1101/2022.04.21.22273340>

Childhood vaccination is among the most effective public health interventions available for the prevention of communicable disease, but coverage in many humanitarian settings is sub-optimal. This systematic review critically evaluated peer-review and grey literature evidence on the effectiveness of system-level interventions for improving vaccination coverage in protracted crises, focusing on how they work, and for whom, to better inform preparedness and response for future crises.

### **[Prosocial motivation for vaccination](#)**

Jonathan Lucas Reddinger, Gary Charness, David Levine  
medRxiv 2022.04.21.22274110; doi: <https://doi.org/10.1101/2022.04.21.22274110>

### **[Disparate Impacts on Online Information Access during the COVID-19 Pandemic](#)**

Jina Suh, Eric Horvitz, Ryen W. White, Tim Althoff  
medRxiv 2021.09.14.21263545; doi: <https://doi.org/10.1101/2021.09.14.21263545> Revision

### **[Public attitudes towards COVID-19 vaccines in Africa: a systematic review](#)**

Patrice Ngangue, Arzouma Hermann Pilabré, Abibata Barro, Yacouba Pafadnam, Nestor Bationo, Dieudonné Soubeiga  
medRxiv 2022.04.19.22274053; doi: <https://doi.org/10.1101/2022.04.19.22274053>

### **[Accuracy of US CDC COVID-19 Forecasting Models](#)**

Aviral Chharia, Govind Jeevan, Rajat Aayush Jha, Meng Liu, Jonathan M Berman, Christin Glorioso  
medRxiv 2022.04.20.22274097; doi: <https://doi.org/10.1101/2022.04.20.22274097>

### **[Implementation strategies to increase human papillomavirus vaccination uptake for adolescent girls in sub-Saharan Africa: A scoping review protocol](#)**

Mwansa Ketty Lubeya, Mulindi Mwanahamuntu, Carla Chibwasha, Moses Mukosha, Mercy Monde Wamunyima, Mary Kawonga  
medRxiv 2022.04.19.22273815; doi: <https://doi.org/10.1101/2022.04.19.22273815>

**[The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance](#)**

Houriiyah Tegally, et al.

medRxiv 2022.04.17.22273906; doi: <https://doi.org/10.1101/2022.04.17.22273906>

*Abstract*

Investment in Africa over the past year with regards to SARS-CoV-2 genotyping has led to a massive increase in the number of sequences, exceeding 100,000 genomes generated to track the pandemic on the continent. Our results show an increase in the number of African countries able to sequence within their own borders, coupled with a decrease in sequencing turnaround time. Findings from this genomic surveillance underscores the heterogeneous nature of the pandemic but we observe repeated dissemination of SARS-CoV-2 variants within the continent. Sustained investment for genomic surveillance in Africa is needed as the virus continues to evolve, particularly in the low vaccination landscape. These investments are very crucial for preparedness and response for future pathogen outbreaks.

**[The French Covid-19 vaccination policy did not solve vaccination inequities: a nationwide longitudinal study on 64.5 million individuals](#)**

F. Débarre, E. Lecoer, L. Guimier, M. Jauffret-Roustide, A.-S. Jannot

medRxiv 2022.01.03.22268676; doi: <https://doi.org/10.1101/2022.01.03.22268676> Revision

**[Predictors of COVID-19 vaccine uptake: An online longitudinal study of US Veterans and non-Veterans](#)**

Alistair Thorpe, Angela Fagerlin, Frank A. Drews, Holly Shoemaker, Federica S. Brecha, Laura D. Scherer

medRxiv 2022.04.19.22273818; doi: <https://doi.org/10.1101/2022.04.19.22273818>

**[Association of Vaccine Hesitancy with Demographics, and Mental Health – United States Household Pulse Survey Study](#)**

Arinjita Bhattacharyya, Shikshita Singh, Swarna Sakshi, Anand Seth, Shesh N Rai

medRxiv 2022.04.13.22273843; doi: <https://doi.org/10.1101/2022.04.13.22273843>

**[COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022](#)**

Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar, Fredrik Kahn

medRxiv 2022.04.14.22273896; doi: <https://doi.org/10.1101/2022.04.14.22273896>

**[Characterization of SARS-CoV-2 vaccine waning in Mexico](#)**

Carlos Hernandez-Suarez, Efren Murillo-Zamora

medRxiv 2022.04.17.22273854; doi: <https://doi.org/10.1101/2022.04.17.22273854>

**[Vaccine effectiveness of CanSino \(Adv5-nCoV\) COVID-19 vaccine among childcare workers – Mexico, March–December 2021](#)**

Vesta L. Richardson, Martín Alejandro Camacho Franco, Aurora Bautista Márquez, Libny Martínez Valdez, Luis Enrique Castro Ceronio, Vicente Cruz Cruz, Radhika Gharpure, Kathryn E. Lafond, Tat S. Yau, Eduardo Azziz-Baumgartner, Mauricio Hernández Ávila

medRxiv 2022.04.14.22273413; doi: <https://doi.org/10.1101/2022.04.14.22273413>

**Wellcome Open Research** [to 23 Apr 2022]  
<https://wellcomeopenresearch.org/browse/articles>  
[Accessed 23 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

*Editorial* metrics NOT PEER REVIEWED

**[Human infection studies: Key considerations for challenge agent development and production](#)** [version 1; peer review: not peer reviewed]

Shobana Balasingam, Sarah Meillon, Cecilia Chui, Alex Mann, Carine La, Charlotte L. Weller, Deborah F. King, Emma Smith

Funders

Wellcome

HIC-Vac

PUBLISHED 22 Apr 2022

*Research Article* metrics AWAITING PEER REVIEW

**[Consortium management structures, processes, and approaches: The DELTAS Africa example](#)** [version 1; peer review: awaiting peer review]

Nadia Tagoe, Sassy Molyneux, Justin Pulford, Sam Kinyanjui

Peer Reviewers Invited

Funder

Wellcome Trust

PUBLISHED 21 Apr 2022

Global efforts to strengthen health research capacity in low- and middle-income countries (LMICs) have intensified in the past few decades, and these efforts are often implemented by consortia. Our review of the literature indicated that reports on health research capacity strengthening (HRCS) consortia have primarily focused on programme outputs and outcomes while management processes and their contributions to consortia goals have received little attention. This qualitative study sought to identify the consortium management processes employed by 10 DELTAS Africa consortia, factors influencing these processes, and leaders' consortium management experiences.

\* \* \* \*

## **Think Tanks**

### **Brookings**

<http://www.brookings.edu/>

Accessed 23 Apr 2022

*Upcoming Event*

**[Profits and the pandemic: Building a more equitable model of capitalism](#)**

April 26, 2022 2:00 PM - 3:00 PM EDT

Online only

*Report*

## **[COVID-19's impact on learning losses and learning inequality in Colombia](#)**

Emiliana Vegas  
Thursday, April 21, 2022

*Report*

### **[Profits and the pandemic: As shareholder wealth soared, workers were left behind](#)**

Molly Kinder, Katie Bach, and Laura Stateler  
Thursday, April 21, 2022

## **Center for Global Development** [to 23 Apr 2022]

<https://www.cgdev.org/>

*Research, Blogs, Publications [Selected]*

Blog Post

### **[Striking While the Iron is Hot: Setting the African Medicines Agency Up for Success](#)**

Morgan Pincombe and Javier Guzman

April 22, 2022

COVID-19 has reinforced the need for strong regulatory systems. The success of new technologies rapidly developed to mitigate the pandemic depends in no small part on key regulatory functions, such as oversight for clinical trials; review and authorization of medical products like vaccines, treatment...

## **Chatham House** [to 23 Apr 2022]

<https://www.chathamhouse.org/>

*Accessed 23 Apr 2022*

[No new digest content identified]

## **CSIS**

<https://www.csis.org/>

*Accessed 23 Apr 2022*

*Upcoming Event*

### **[Equity in Immunization Services to Ensure "A Long Life for All"](#)**

April 28, 2022

*Upcoming Event*

### **[Innovation and IP's Role in Combatting the Covid-19 Pandemic](#)**

April 27, 2022

*Upcoming Event*

### **[AMR as a Global Security Threat: Destabilizing Food Systems and Healthy Communities](#)**

April 25, 2022

## **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 23 Apr 2022*

*Accessed 23 Apr 2022*



[No new digest content identified]

**ODI [Overseas Development Institute]** [to 23 Apr 2022]

<https://odi.org/en/publications/>

*Publications*

*Accessed 23 Apr 2022*

[No new digest content identified]

**Rand** [to 23 Apr 2022]

<https://www.rand.org/pubs.html>

*Reports, Selected Journal Articles*

*No new digest content identified.*

**Urban Institute** [to 23 Apr 2022]

<https://www.urban.org/publications>

*Research Publications*

*Brief*

[\*\*Best Practices in Education to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

*Brief*

[\*\*Best Practices in Safety Net Programs to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

*Brief*

[\*\*Best Practices in Housing, Transportation, and Infrastructure to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

*Brief*

[\*\*Best Practices in Small Business Recovery to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

*Brief*

[\*\*Best Practices in Employment to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

*Brief*

[\*\*Best Practices in Local Revenue Recovery to Inform an Equitable COVID-19 Recovery\*\*](#)

April 12, 2022

\* \* \* \*

**Media Watch**

## [The Economist this week A special edition on our coronavirus rage coverage](#)

April 23rd 2022

Covid-19's economic fallout shows no signs of abating. Our cover story looks at America's Federal Reserve, which has failed to tackle the inflation fuelled by the country's pandemic stimulus. Across the Atlantic, European economies are adjusting to the end of the ECB's pandemic bond-buying scheme.

The focus is once again on China, where cases continue to rise, reflecting low vaccination rates among the elderly and an ineffective local vaccine. Attempts to quash the virus are wreaking havoc on the economy, while elitist rules expose ancient geographic inequalities. Officials are baselessly blaming foreign imports for outbreaks...

### **New York Times**

April 23, 2022 Updated 2:45 p.m. ET

*Global Health*

#### [The Drive to Vaccinate the World Against Covid Is Losing Steam](#)

*Rates are stalling in most low-income countries well short of the W.H.O.'s goal to immunize 70 percent of people in every nation. Some public health experts believe the momentum is gone forever.*

By [Rebecca Robbins](#) and [Stephanie Nolen](#)

In the middle of last year, the World Health Organization began promoting an ambitious goal, one it said was essential for ending the pandemic: fully vaccinate 70 percent of the population in every country against Covid-19 by June 2022.

Now, it is clear that the world will fall far short of that target by the deadline. And there is a growing sense of resignation among public health experts that high Covid vaccination coverage may never be achieved in most lower-income countries, as badly needed funding from the United States dries up and both governments and donors turn to other priorities.

"The reality is that there is a loss of momentum," said Dr. Isaac Adewole, a former health minister of Nigeria who now serves as a consultant for the Africa Centers for Disease Control and Prevention.

Only a few of the world's 82 poorest countries — including Bangladesh, Bhutan, Cambodia and [Nepal](#) — have reached the 70 percent vaccination threshold. Many are under 20 percent, according to data compiled from government sources by the [Our World in Data](#) project at the University of Oxford.

By comparison, about two-thirds of the world's richest countries have reached 70 percent. (The United States is at 66 percent.)

The consequences of giving up on achieving high vaccination coverage worldwide could prove severe. Public health experts say that abandoning the global effort could lead to the emergence of dangerous new variants that would threaten the world's precarious efforts to live with the virus.

"This pandemic is not over yet — far from it — and it's imperative that countries use the doses available to them to protect as much of their population as possible," said Dr. Seth Berkley, chief executive of Gavi, the nonprofit that runs the global vaccine clearinghouse Covax.

Countries in different parts of the world, including some in Eastern Europe and the Middle East, have seen their vaccination rates stagnate in recent months at a third or less of their populations. But Africa's vaccination rate remain the most dismal.

Fewer than 17 percent of Africans have received a primary Covid immunization. Nearly half of the vaccine doses delivered to the continent thus far have gone unused. Last month, the number of doses injected on the continent fell by 35 percent compared to February. W.H.O. officials attributed the drop to mass vaccination pushes being replaced by smaller-scale campaigns in several countries.

Some global health experts say the world missed a prime opportunity last year to provide vaccines to lower-income countries, when the public was more fearful of Covid and motivated to get vaccinated.

"There was a time people were very desperate to get vaccinated, but the vaccines were not there. And then they realized that without the vaccination, they didn't die," said Dr. Adewole, who wants to see countries continue to pursue the 70 percent target.

What momentum remains in the global vaccination campaign has been hindered by a shortfall in funding for the equipment, transportation and personnel needed to get shots into arms.

In the United States, a key funder of the vaccination effort, lawmakers stripped \$5 billion meant for global pandemic aid from the coronavirus response package that is expected to come up for a vote in the next few weeks. Biden administration officials have said that without the funds, they will be unable to provide support for vaccine delivery to more than 20 under-vaccinated countries.

Some public health experts point to reasons for optimism that the global vaccination campaign still has steam. Despite the drop off from the February peak, the number of Covid vaccinations being administered each day in Africa is still near a pandemic high. And Gavi earlier this month drew a significant new round of funding pledges, securing \$4.8 billion in commitments, although it fell short of its \$5.2 billion goal.

There is also hope that a global Covid summit the White House plans to co-host next month could be an opportunity to generate momentum and funding.

But the drop in public demand has led some health officials and experts to quietly, and in some cases outright, question whether the 70 percent vaccination target is feasible or even sensible.

Reported fatalities from Covid-19 remain comparatively low in sub-Saharan Africa, although there is debate about how much of this reflects poor data tracking. The perception, however, in many countries in the region is that the disease does not pose a serious threat, certainly not as much as other pervasive health problems that demand attention with scarce health care resources.

Many lower-income governments are turning their focus to their economies and other health issues like H.I.V., said Fifi Rahman, a civil society representative to a W.H.O.-launched group coordinating the global Covid response. "There's a sense of a lot of competing priorities, but that's a symptom of the momentum being gone. Because when the momentum was there, everyone was like, 'Where are our vaccines?'"

In rural areas of the Democratic Republic of Congo, for example, where the reported Covid death rate is very low, there is a surge in measles cases threatening 20 million children. Yet the government says it cannot spare the resources to provide supplementary measles vaccinations this year, said Christopher Mambula, medical manager for Doctors Without Border in East Africa. In this kind of context, it makes little sense to continue to divert resources to widespread vaccination against Covid, he said.

As African governments have received more vaccines donated from wealthy countries and struggled to distribute even those supplies, their interest in ordering more doses has dropped.

The African Union still aims to vaccinate 70 percent of its population by the end of 2022. But with countries slow to use up donated vaccines, the bloc has not exercised its options to order more doses of the shots from Johnson & Johnson and Moderna.

The South African drugmaker Aspen Pharmacare earlier this year finalized a deal to bottle and market the Johnson & Johnson vaccine across Africa, a contract that was billed as an early step toward Africa's development of a robust vaccine production industry. Aspen geared up for production, but no buyers, including the African Union and Covax, have placed orders yet, said Stephen Saad, Aspen's chief executive.

The Serum Institute of India, the world's largest vaccine maker, stopped its production of Covid shots in December last year, when its stockpile grew to 200 million doses; Bharat Biotech, another Indian firm that was a major producer, also stopped making vaccines in the face of low demand. The companies say they have no further orders since their contracts with the Indian government ended in March.

After the W.H.O. began promoting the 70 percent vaccination goal, many lower-income governments adopted the target for their own populations. The Biden administration also endorsed it last September, setting a deadline of September 2022.

At the time, two doses of the vaccines from Pfizer and Moderna were understood to offer very strong protection against even mild disease, and there was still hope that achieving high levels of vaccination coverage would tame the virus. But the emergence of new variants and the spread of the virus in Africa changed the calculus.

The vaccine regimens that had been planned for the developing world offered little protection against infection with the Omicron variant. And as sub-Saharan African countries were shut out of vaccine distribution for much of last year, more and more Africans gained protection against the virus from natural infection, which studies have shown works as well as two mRNA doses in preventing infection. New data from the W.H.O. shows that at least two-thirds of Africans had been infected with the virus before the Omicron wave.

Given these factors, some public health experts in Africa say the broad 70 percent goal no longer makes sense. "There's very little value to it. In fact, we will gain much more by getting to more than 90 percent of people above the age of 50," said Shabir Madhi, a professor of vaccinology and the dean of the faculty of health sciences at the University of the Witwatersrand in Johannesburg. About two-thirds of South Africans above age 50 are currently fully vaccinated.

Dr. Madhi said that South Africa could close down mass vaccination sites and instead redouble its efforts to seek out the most vulnerable at church services and at government offices that pay out monthly pension benefits.

Katherine O'Brien, who directs the W.H.O.'s work on vaccines and immunizations, said the agency encourages countries to focus on its most vulnerable citizens rather than vaccinating "a random set of 70 percent" of their populations. The aspiration she said, has always been "100 percent of health workers, 100 percent of older adults, 100 percent of pregnant women, 100 percent of the people who fall into those highest risk groups."

Countries can of course make decisions about what health goal they wish to prioritize, Dr. O'Brien said, but finite resources should not be the obstacle to vaccinating against the coronavirus. "The world has enough resources to do this, if countries want to do it," she said. "And that should be really the North Star."

Some public health experts said that while the 70 percent vaccination threshold is clearly not achievable by its original deadline, it would be unwise and unethical to give up on that target over a longer time horizon. They expressed frustration about the growing gulf between wealthy countries vaccinating young children and offering healthy adults fourth vaccine doses, and the regions where the majority of people still do not have one dose.

"Why are we making it one target for high-income countries and one target for low income?" said Dr. Ayode Alakija, a co-chair of the African Union's vaccine delivery program.

She said that even though many people in sub-Saharan Africa have been infected, there is still need for the additional protection that would come from a high level of vaccination coverage.

Modest vaccination coverage, she said, "is not considered a good enough level of protection in England, it's not a good enough level of protection in America. How is it OK not to be aiming for the very maximum, maximum we can? Aim for the sky and get to the top of the tree."

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](http://cvep.org))/GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*